

B2 cont'd
transcriptional start site of the CEA gene and a CEA enhancer.

B3
38. (amended) A composition comprising the adenovirus vector of claim 33, and a pharmaceutically acceptable excipient.

B3
39. A host cell transformed with the adenovirus vector of claim 33.

B4
40 (new) The adenovirus vector of Claim 33, wherein said adenovirus gene essential for replication is an early gene.

B4
41. (new) The adenovirus vector of Claim 40, wherein said early gene is selected from the group consisting of E1A, E1B and E4.

42. (new) The adenovirus vector of Claim 33, wherein said first and said second adenovirus gene essential for replication are E1A and E1B.

43. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a nucleotide sequence from about -6.1 to about -3.8 relative to the transcriptional start site of the CEA gene.

44. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a nucleotide sequence from about -14.5 to about -3.8 relative to the transcriptional start site of the CEA gene.

45. (new) The adenovirus vector of Claim 36 wherein said CEA promoter comprises the nucleotide sequence as shown in SEQ ID NO:1.

46. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises a nucleotide sequence within the region from about -13.6 to about -10.6 relative to the transcriptional start site of the CEA gene.

47. (new) The adenovirus vector of Claim 36 wherein said CEA enhancer comprises the nucleotide sequence from about -14.5 to about -10.6 relative to the transcriptional start site of the CEA gene.